Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.

Wolchok JD, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Butler MO, Hill A, Márquez-Rodas I, Haanen JBAG, Guidoboni M, Maio M, Schöffski P, Carlino MS, Lebbé C, McArthur G, Ascierto PA, Daniels GA, Long GV, Bas T, Ritchings C, Larkin J, Hodi FS

Open source

DOI: 10.1200/jco.21.02229
Published: 2022 Jan 10
Container: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1200/jco.21.02229,
  title = {Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.},
  author = {Wolchok JD and Chiarion-Sileni V and Gonzalez R and Grob JJ and Rutkowski P and Lao CD and Cowey CL and Schadendorf D and Wagstaff J and Dummer R and Ferrucci PF and Smylie M and Butler MO and Hill A and Márquez-Rodas I and Haanen JBAG and Guidoboni M and Maio M and Schöffski P and Carlino MS and Lebbé C and McArthur G and Ascierto PA and Daniels GA and Long GV and Bas T and Ritchings C and Larkin J and Hodi FS},
  year = {2022},
  journal = {Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  doi = {10.1200/jco.21.02229},
  url = {https://doi.org/10.1200/jco.21.02229}
}

RIS

TY  - JOUR
TI  - Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.
AU  - Wolchok JD
AU  - Chiarion-Sileni V
AU  - Gonzalez R
AU  - Grob JJ
AU  - Rutkowski P
AU  - Lao CD
AU  - Cowey CL
AU  - Schadendorf D
AU  - Wagstaff J
AU  - Dummer R
AU  - Ferrucci PF
AU  - Smylie M
AU  - Butler MO
AU  - Hill A
AU  - Márquez-Rodas I
AU  - Haanen JBAG
AU  - Guidoboni M
AU  - Maio M
AU  - Schöffski P
AU  - Carlino MS
AU  - Lebbé C
AU  - McArthur G
AU  - Ascierto PA
AU  - Daniels GA
AU  - Long GV
AU  - Bas T
AU  - Ritchings C
AU  - Larkin J
AU  - Hodi FS
PY  - 2022
JO  - Journal of clinical oncology : official journal of the American Society of Clinical Oncology
DO  - 10.1200/jco.21.02229
UR  - https://doi.org/10.1200/jco.21.02229
ER  -

APA

JD, W., V, C., R, G., JJ, G., P, R., CD, L., CL, C., D, S., J, W., R, D., PF, F., M, S., MO, B., A, H., I, M., JBAG, H., M, G., M, M., P, S., MS, C., C, L., G, M., PA, A., GA, D., GV, L., T, B., C, R., J, L., & FS, H. (2022). Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. https://doi.org/10.1200/jco.21.02229

Source records

pubmed · retrieved 2026-09-27T10:37:19.723Z